Eilean Therapeutics Australia

Eilean Therapeutics is a clinical-stage biotechnology company focused on developing next-generation small molecule therapies for hematologic malignancies, with a primary emphasis on overcoming resistance in acute myeloid leukemia (AML). The company utilizes a sophisticated discovery platform that combines AI-driven design with deep expertise in protein structure and medicinal chemistry. Its pipeline includes highly selective inhibitors targeting FLT3, NRAS, and SHP2, designed to address the limitations of current standard-of-care treatments. Eilean frequently leverages the Australian clinical trial ecosystem for early-stage human studies of its lead candidates, operating through its subsidiary Eilean Therapeutics Australia.